Revumenib (menin inhibitor)

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-07-29 — Revumenib in Patients With Myelofibrosis: Phase Ib/II trial (trial-early) evaluates revumenib as monotherapy in myelofibrosis after prior JAK-inhibitor therapy (COHORT-1) and in combination with a JAK inhibitor (COHORT-2); no outcome data reported yet. (novelty: 3)

Open questions

Related